Michael Bell is currently a Research Analyst at Point72, specializing in long/short biotechnology, a position held since November 2025. Previously, Michael served as a Biotechnology Equity Research Associate at Cantor Fitzgerald from September 2023 to October 2025, working under Eric Schmidt and Josh Schimmer. Earlier experience includes a role as a Private Equity Value Creation Intern at Strategy& within the PwC Network in summer 2022, and a New Product Commercialization Intern at Neurocrine Biosciences, focusing on pipeline strategy and indication prioritization in summer 2021. Michael's research background includes independent studies in computational chemistry and a role as a Microbiology Research Assistant at Oakland University, where studies were conducted from September 2018 to May 2021. Michael holds a Master of Science in Biomedical Engineering from Columbia University and a Bachelor of Science in Biochemistry from Oakland University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices